New
HealthMore in Health→
Oral Icotrokinra Shows Promise in Ulcerative Colitis Trial
Key Takeaways
- All three tested icotrokinra doses beat placebo for clinical response at week 12.
- The 400-mg dose showed higher clinical remission and endoscopic improvement rates than placebo.
- Larger, longer trials are needed to confirm benefits and assess safety.
DE
DT Editorial Team··via medicalxpress.com